Last updated: September 2, 2026
The fixed-dose hepatitis C regimen containing dasabuvir sodium, ombitasvir, paritaprevir, and ritonavir was commercialized by AbbVie as Viekira Pak and Viekira XR. It generated more than $5 billion in disclosed global revenue during 2015-2017 but rapidly lost commercial relevance after the launch of simpler, shorter-duration, pangenotypic regimens, particularly AbbVie’s Mavyret. The products remain FDA-approved legacy therapies, but they have little current strategic value compared with newer direct-acting antivirals.
What drug products contain dasabuvir sodium, ombitasvir, paritaprevir, and ritonavir?
The four-drug combination is marketed as Viekira Pak and Viekira XR.
| Product |
Active ingredients |
FDA approval |
Primary use |
| Viekira Pak |
Ombitasvir, paritaprevir, ritonavir, dasabuvir tablets |
December 19, 2014 |
Chronic hepatitis C, primarily genotype 1 |
| Viekira XR |
Extended-release dasabuvir with ombitasvir, paritaprevir, and ritonavir |
July 2016 |
Chronic hepatitis C, primarily genotype 1 |
| Technivie |
Ombitasvir, paritaprevir, ritonavir without dasabuvir |
July 24, 2015 |
Genotype 4 hepatitis C without cirrhosis |
Viekira Pak uses two tablets of ombitasvir, paritaprevir, and ritonavir once daily plus dasabuvir twice daily. Viekira XR consolidated the regimen into once-daily dosing. Ritonavir is included as a pharmacokinetic enhancer for paritaprevir rather than as the principal antiviral component. The regimen inhibits multiple hepatitis C viral targets, including NS3/4A protease, NS5A, and NS5B polymerase.
The products were designed for genotype 1 infection and required ribavirin for certain patient groups. Their genotype coverage, drug-interaction burden, tablet complexity, and safety restrictions limited adoption as the hepatitis C market moved toward pangenotypic therapies.
How did Viekira Pak and Viekira XR perform financially?
Viekira Pak produced rapid revenue growth after launch, followed by a steep decline as prescriber preferences shifted to competing direct-acting antivirals.
| Year |
Reported AbbVie HCV product revenue |
Market interpretation |
| 2014 |
Commercial launch late in year |
Initial launch period |
| 2015 |
Approximately $1.64 billion |
First full commercial year |
| 2016 |
Approximately $2.28 billion |
Revenue peak |
| 2017 |
Approximately $1.02 billion |
Sharp erosion from competing regimens |
| 2018 onward |
Declining and increasingly immaterial relative to AbbVie’s portfolio |
Displacement by Mavyret and other pangenotypic products |
AbbVie reported Viekira Pak and related Viekira products as a major HCV revenue contributor in 2015 and 2016. Revenue fell by more than half in 2017. The decline occurred even while the total hepatitis C treatment market remained commercially significant because competing products offered better convenience and broader genotype coverage. AbbVie’s Mavyret became the company’s replacement HCV franchise.
The revenue trajectory illustrates the short commercial life cycle typical of oral direct-acting antivirals. Patent protection did not prevent competitive erosion because therapeutic substitution occurred before large-scale generic entry.
Why did the market decline so quickly?
The principal market driver was therapeutic displacement, not immediate patent expiry.
Mavyret changed AbbVie’s product strategy
Mavyret, containing glecaprevir and pibrentasvir, was approved in 2017. It offered:
- Pangenotypic coverage across HCV genotypes 1 through 6.
- An eight-week treatment option for many patients without cirrhosis.
- A three-tablet daily regimen.
- No ritonavir booster.
- Lower interaction and monitoring complexity than the Viekira regimen.
Mavyret competed directly with Viekira products while also expanding AbbVie’s addressable market. AbbVie’s annual reports identified Viekira erosion as a consequence of Mavyret uptake and broader market competition. [1-3]
Competing products had stronger prescribing attributes
Harvoni, Epclusa, Zepatier, and Mavyret shifted treatment decisions toward pangenotypic or simplified regimens. Viekira’s genotype 1 positioning became commercially narrow, particularly after treatment guidelines increasingly favored pangenotypic therapy.
The regimen also carried clinically important restrictions. Viekira products were contraindicated in patients with moderate or severe hepatic impairment and were associated with serious liver injury reports in patients with advanced liver disease. Ritonavir created substantial drug-interaction considerations. [4]
Payer economics reduced the value of the legacy regimen
HCV payers increasingly used preferred-product strategies, rebates, and treatment pathways favoring lower-cost pangenotypic regimens. List prices were less important than net prices, rebates, and formulary placement. The resulting price competition accelerated the decline of older genotype-specific therapies.
When did Viekira Pak lose exclusivity?
FDA regulatory exclusivity and patent exclusivity are separate.
Viekira Pak received approval in December 2014. Its new chemical entity exclusivity period generally protected the approved drug from submission of a competing abbreviated new drug application for five years, subject to the specific regulatory status of the active ingredients and application. That period would have ended around late 2019 absent a patent or pediatric extension.
The commercial loss of exclusivity occurred earlier in practical terms because physicians and payers moved to newer products. The key distinction is:
| Type of protection |
Approximate effect |
| FDA approval exclusivity |
Protected the initial NDA period |
| Orange Book patents |
Could delay approval or launch of specified generic products |
| Clinical differentiation |
Deteriorated rapidly after pangenotypic competitors launched |
| Commercial exclusivity |
Effectively weakened during 2017-2019 |
A precise generic launch date cannot be inferred solely from the end of FDA exclusivity. A generic applicant would also need to address Orange Book-listed patents, formulation claims, method-of-use claims, and any settlement restrictions.
What patents protect dasabuvir, ombitasvir, paritaprevir, and ritonavir?
The patent estate is built around several technical layers rather than a single composition-of-matter patent.
Core antiviral compound patents
The foundational estate covers:
- Dasabuvir and related non-nucleoside NS5B polymerase inhibitors.
- Ombitasvir and related NS5A inhibitors.
- Paritaprevir and related NS3/4A protease inhibitors.
- Pharmaceutical salts, solvates, stereoisomers, and crystalline forms.
Dasabuvir sodium is a salt form of dasabuvir used in the commercial formulation. Salt and solid-state claims can extend protection beyond the earliest compound claims, although their enforceability depends on claim scope, patent prosecution history, prior art, and validity challenges.
Combination and formulation patents
The estate also includes claims directed to:
- Fixed-dose combinations of ombitasvir, paritaprevir, ritonavir, and dasabuvir.
- Dosage forms containing the active ingredients in defined ratios.
- Extended-release dasabuvir formulations used in Viekira XR.
- Tablet compositions, excipients, coatings, and dissolution profiles.
- Treatment protocols using the combination with or without ribavirin.
Formulation patents matter most when the active-ingredient composition patent has expired or is vulnerable. They generally do not prevent every possible generic formulation unless the generic product practices the asserted claims.
Method-of-use patents
Method claims cover treatment of HCV infection, including:
- Genotype 1 infection.
- Genotype-specific treatment regimens.
- Treatment with or without ribavirin.
- Patients with specified cirrhosis or treatment histories.
- Duration and dosing schedules.
- Use of the combination with other antiviral agents.
Method-of-use patents can support a patent certification or litigation strategy even when a generic applicant seeks approval for a narrower, non-infringing label. Their practical value depends on prescribing behavior and the feasibility of a skinny-label launch.
What is the Orange Book status of Viekira Pak?
Viekira Pak was approved under NDA 206619. Viekira XR was approved under a related NDA for the extended-release presentation. The FDA Orange Book historically listed patents associated with these products, including patents covering active ingredients, combinations, formulations, and methods of use.
The relevant commercial question is not whether a patent was once listed. It is whether a listed patent remains unexpired, enforceable, and relevant to the proposed generic product. HCV patent estates can include different expiration dates for compound, formulation, and method claims. FDA listing records should be reviewed by NDA and patent number at the time of a proposed filing. [5]
The product’s current patent strength is materially lower than its original position because:
- The original launch date was more than a decade ago.
- FDA exclusivity has expired.
- Older compound claims are approaching or have reached their nominal expiration windows.
- Commercial demand has shifted to competing products.
- A generic applicant may have little incentive to challenge residual patents for a shrinking market.
Which companies challenged Viekira Pak patents?
No major generic company has achieved a commercially significant U.S. launch of a substitutable Viekira Pak product. Publicly visible HCV competition was driven primarily by branded products rather than generic entry.
The absence of a major generic launch does not establish that every Viekira patent was unchallenged. Generic applicants can file Paragraph IV certifications without ultimately launching, and patent disputes can resolve through confidential or lightly reported agreements. The commercial record indicates that branded displacement was more important than Paragraph IV litigation in determining Viekira’s decline.
What Paragraph IV risks exist for the combination?
A Paragraph IV applicant would face several possible strategies:
| Strategy |
Potential benefit |
Principal barrier |
| Full-combination ANDA |
Direct substitution for Viekira Pak |
Multiple active ingredients and complex bioequivalence requirements |
| Skinny-label ANDA |
Avoids selected method-of-use claims |
Limited commercial demand and prescribing restrictions |
| Formulation design-around |
Avoids specific tablet or release claims |
May require new formulation development |
| Patent challenge |
Removes launch barrier |
Litigation cost exceeds likely market value |
| Authorized generic or license |
Faster regulatory path |
Requires agreement with patent holder |
The main risk to AbbVie is not a large generic wave. It is residual pricing pressure, niche substitution, and erosion of any remaining revenue from patients or markets where Viekira remains available.
What is the FDA regulatory status of Viekira Pak?
Viekira Pak remains an FDA-approved prescription product unless FDA records show a later withdrawal of the approval itself. Approval status and commercial availability are different. A sponsor can stop marketing a product without immediately withdrawing the NDA.
The FDA-approved labeling includes major limitations involving hepatic impairment, drug interactions, and coadministration with certain medicines. The ritonavir component creates a particularly broad interaction profile because it affects cytochrome P450 enzymes and transport pathways. [4]
The regimen has no biosimilar pathway because it is a small-molecule chemical drug, not a biologic. Any follow-on product would normally use the ANDA pathway or, depending on the proposed changes, a 505(b)(2) pathway.
How does Viekira compare with Mavyret and other HCV drugs?
| Attribute |
Viekira Pak |
Mavyret |
Epclusa |
| Core components |
Ombitasvir, paritaprevir, ritonavir, dasabuvir |
Glecaprevir, pibrentasvir |
Sofosbuvir, velpatasvir |
| Genotype coverage |
Primarily genotype 1 |
Genotypes 1-6 |
Genotypes 1-6 |
| Booster required |
Yes, ritonavir |
No |
No |
| Typical regimen complexity |
Multiple tablets, with dosing distinctions |
Three tablets once daily |
One tablet once daily |
| Main commercial position |
Legacy genotype-specific therapy |
Broad first-line therapy |
Broad pangenotypic therapy |
| Current competitive strength |
Low |
High relative to Viekira |
High relative to Viekira |
Mavyret is the most relevant direct comparison because it is AbbVie’s successor HCV franchise. Epclusa and other pangenotypic products further reduced the strategic value of a genotype 1-specific regimen.
What manufacturing and intellectual-property barriers remain?
Manufacturing a four-drug combination is more difficult than manufacturing a single-tablet pangenotypic product. Key barriers include:
- Production of multiple active pharmaceutical ingredients.
- Control of salt and solid-state forms.
- Tablet compatibility and stability.
- Drug-release control for dasabuvir.
- Analytical methods for four active ingredients.
- Bioequivalence testing for a complex regimen.
- Supply-chain coordination across several drug substances.
- Labeling and interaction-management requirements.
These barriers are technical rather than commercially decisive. A capable generic manufacturer could potentially address them, but the expected market opportunity may not justify the development and litigation expense.
Geographic coverage also matters. Patent rights are territorial, regulatory approvals differ by jurisdiction, and commercial withdrawal in one country does not establish withdrawal elsewhere. European and other national patent positions should be analyzed separately from U.S. Orange Book listings.
What licensing deals affected the commercial position?
AbbVie’s HCV franchise was supported by licensed or partnered technology related to the component antivirals, particularly the research and development programs underlying paritaprevir and ombitasvir. The most important commercial relationship was AbbVie’s internal integration of these assets into the Viekira and Mavyret franchises.
The financial impact of licensing is difficult to isolate from public filings because royalty obligations and milestone economics can be disclosed at a portfolio level rather than by individual active ingredient. No licensing transaction changed the core market outcome: the products were displaced by newer regimens before patent expiry became the principal competitive event.
What generic launch scenarios exist for Viekira Pak?
Scenario 1: No meaningful U.S. generic launch
This is the most commercially plausible outcome. The remaining market is small, the product is operationally complex, and prescribers have better alternatives.
Scenario 2: Limited niche launch
A generic could enter selected channels, institutional accounts, or international markets where Viekira remains listed in treatment protocols. Volume would likely be limited.
Scenario 3: Authorized or licensed supply
A patent holder or third party could support continued supply through licensing or an authorized-generic arrangement. This would reduce litigation risk but would not restore the product’s former revenue scale.
Scenario 4: International low-price competition
In lower-income markets, price can preserve demand for older HCV regimens. However, regulatory, procurement, and guideline conditions vary widely. International volume would not necessarily translate into substantial U.S. revenue.
How strong is the current patent estate?
The current estate is commercially weak despite having been technically layered.
| Factor |
Current assessment |
| Composition-of-matter protection |
Aged and increasingly vulnerable to expiration |
| Combination claims |
Potentially relevant but narrower than original compound claims |
| Formulation claims |
More important for Viekira XR and specific dosage forms |
| Method-of-use claims |
Potentially enforceable but vulnerable to skinny-label strategies |
| Regulatory exclusivity |
Expired |
| Biosimilar risk |
None |
| Generic substitution risk |
Low to moderate, depending on jurisdiction |
| Commercial erosion risk |
High and already realized |
| Revenue recovery potential |
Minimal |
The strongest remaining barrier is likely the cost-benefit imbalance facing a generic applicant rather than a single blocking patent. Patent rights can delay a launch, but they cannot reverse clinical obsolescence.
What is the investment and revenue exposure?
Viekira was once a material contributor to AbbVie’s revenue and hepatitis C strategy. Its value has since migrated to Mavyret and other higher-utility antiviral products.
For investors, the relevant exposure is:
- Minimal current revenue contribution relative to AbbVie’s total portfolio.
- No material biosimilar issue.
- Limited probability of a high-value generic litigation event.
- Greater relevance as a case study in rapid therapeutic substitution.
- Residual liability tied to product supply, pharmacovigilance, labeling, and potential patent disputes.
- No credible pathway back to peak-period sales without a major change in treatment guidelines or supply conditions.
Key Takeaways
- Dasabuvir sodium, ombitasvir, paritaprevir, and ritonavir were commercialized primarily as Viekira Pak and Viekira XR.
- AbbVie’s reported HCV revenue peaked at roughly $2.28 billion in 2016 and fell to approximately $1.02 billion in 2017.
- Mavyret, Epclusa, Harvoni, and other pangenotypic regimens drove the decline before generic entry became the main threat.
- FDA exclusivity has expired, and the product’s patent estate is now an aging combination of compound, formulation, and method-of-use claims.
- The products are small-molecule drugs and have no biosimilar exposure.
- A commercially significant U.S. generic launch is unlikely because the remaining market is narrow and the regimen is complex.
- The combination’s strategic value is now primarily historical, regulatory, and patent-analytic rather than revenue-generating.
FAQs
Is dasabuvir sodium sold as a standalone hepatitis C drug?
No. Dasabuvir sodium was commercialized as part of a multidrug regimen with ombitasvir, paritaprevir, and ritonavir. It was not positioned as a standalone antiviral product.
Is Viekira Pak still used for hepatitis C treatment?
Use is limited. Current treatment practice generally favors pangenotypic regimens with simpler dosing, broader genotype coverage, and fewer interaction concerns.
Can a generic manufacturer copy Viekira Pak after FDA exclusivity expired?
Not automatically. A generic applicant must address applicable Orange Book patents and demonstrate bioequivalence for the complex combination product. FDA exclusivity expiry removes one barrier but does not eliminate patent or development requirements.
Does Viekira Pak have biosimilar competition?
No. Viekira Pak is a small-molecule drug product. Biosimilar provisions apply to biologics, not conventional chemical medicines.
Which AbbVie product replaced Viekira Pak?
Mavyret became AbbVie’s principal hepatitis C product. It offered pangenotypic coverage and a simpler treatment regimen, making it substantially more competitive than Viekira Pak.
References
-
AbbVie Inc. (2016). 2015 annual report. AbbVie.
-
AbbVie Inc. (2017). 2016 annual report. AbbVie.
-
AbbVie Inc. (2018). 2017 annual report. AbbVie.
-
U.S. Food and Drug Administration. (2019). Viekira Pak prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
